NextGen Bio
Filter News
Found 7,364 articles
-
Chroma Medicine to Showcase Data Demonstrating Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR T at 65th ASH Annual Meeting
11/2/2023
Chroma Medicine, Inc. announced that it will present a poster demonstrating the potential of its multiplex epigenetic editing platform at the American Society of Hematology 65th Annual Meeting, taking place December 9-12, 2023, in San Diego, CA.
-
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/1/2023
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced financial results for the third quarter ended September 30, 2023 and provided a general business update.
-
Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies
10/25/2023
Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies.
-
Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2
10/24/2023
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, announced positive interim results in its Phase 1b clinical study of UPB-101, a thymic stromal lymphopoietin receptor inhibitor.
-
Totus Medicines Appoints John Maraganore to Scientific Advisory Board
10/19/2023
Totus Medicines, the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, is pleased to announce the appointment of John Maraganore, Ph.D., to the company's Scientific Advisory Board.
-
Epic Bio to Present at the Upcoming Annual European Society of Gene and Cell Therapy
10/19/2023
Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced four poster presentations at the upcoming European Society of Gene and Cell Therapy taking place October 24-27, 2023, in Brussels, Belgium.
-
Epic Bio Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
10/17/2023
Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, announced that Weston Miller, M.D., will join the company as chief medical officer effective October 23, 2023.
-
Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of Directors
9/27/2023
Chroma Medicine, Inc. announced the addition of innovative biotech business leader Michael A. Kelly to its Board of Directors.
-
Chroma Medicine Presents Data Showing Specific and Durable HBV Silencing with Epigenetic Editors at the HBV International Meeting 2023
9/20/2023
Chroma Medicine, Inc., a genomic medicine company pioneering single-dose epigenetic editing therapeutics, presented positive preclinical data demonstrating the potential of its epigenetic editors to produce efficacious, specific, and durable silencing of the hepatitis B virus during the HBV International Meeting 2023, held September 19-23 in Kobe, Japan.
-
The first annual BioTechX USA, held in Santa Clara in September, bridged the communication gap by bringing together life sciences leaders in all areas of the industry.
-
Forbion co-leads $175 million Series B financing of Mariana Oncology as first investment of Forbion Ventures Fund VI
9/7/2023
Forbion, a leading European life sciences venture capital firm, announces that it has co-led, together with Deep Track Capital, an oversubscribed $175 million Series B financing in Mariana Oncology, the first investment by its Forbion Ventures Fund VI.
-
Mariana Oncology Announces $175 Million Series B Financing
9/7/2023
Mariana Oncology Inc., a biotechnology company pioneering a new era of radiopharmaceutical innovation to treat cancers with high unmet need, announced the closing of an oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion.
-
Septerna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies
8/31/2023
Septerna announced the addition of David Martin, Ph.D., as Senior Vice President of Development Sciences, and Samira Shaikhly as Chief People Officer to its leadership team.
-
Epic Bio Named a “Fierce 15” Company by Fierce Biotech
8/28/2023
Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, has been named to Fierce Biotech’s 2023 “Fierce 15” list, designating it as one of the most outstanding early-stage biotechnology companies in the industry.
-
Neumora Therapeutics Names Henry Gosebruch as President and Chief Executive Officer
7/18/2023
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, announced the appointment of Henry Gosebruch as president and chief executive officer and a member of the Company’s board.
-
Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder
7/18/2023
Neumora Therapeutics, Inc. announced the planned initiation of the KOASTAL Program, a Phase 3 pivotal clinical program designed to evaluate the efficacy and safety of navacaprant monotherapy for the treatment of major depressive disorder.
-
Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines
7/11/2023
Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors, announced the closing of a $150 million Series B financing.
-
European Patent Office Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies
6/27/2023
ONK Therapeutics Ltd announced that the European Patent Office has granted its licensed patent covering CISH knockout in NK cells, irrespective of the source of the NK cells, including human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem cells.
-
Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD
6/16/2023
Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented new non-human primate data supporting the clinical advancement of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.
-
Seismic Therapeutic Announces Presentation of Preclinical Data for Advancing Novel Biologics Drug Programs at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies
6/14/2023
Seismic Therapeutic, Inc. announced nine poster presentations supporting the company’s emerging pipeline of novel biologics derived from its proprietary IMPACT platform to treat autoimmune diseases at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies taking place on June 20-23 in Boston, MA.